Want to see JNJ full AI Analyst Report?
Earnings Data
Report Date
Jul 15, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.86Last Year’s EPS
2.77Same Quarter Last Year
Moderate Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a broadly positive commercial and pipeline story: strong top-line operational growth, multiple high-growth products (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT, TREMFYA) and successful new launches (ICOTYDE, INLEXZO) with raised full‑year guidance and clear long‑term targets (line of sight to double‑digit growth by decade end). Offsetting these positives were significant short‑term headwinds—most notably a steep STELARA decline, GAAP EPS volatility driven by prior-year one‑time items, margin deleverage from heavier launch investments and a soft Q1 free cash flow run‑rate. Management emphasized confidence in recovery/acceleration through the year, substantial R&D and manufacturing investments, and multiple upcoming catalysts, leading to an overall constructive outlook despite near‑term profitability and comparability pressures.Company Guidance
Company-wide Operational Sales Growth and Revenue
Q1 2026 worldwide sales of $24.1 billion with operational sales growth of 6.4% (reported midpoint guidance implies $100.8B for 2026). Excluding STELARA headwind (~540 bps), the company grew in double digits in the quarter. U.S. growth was 8.3% and ex-U.S. growth was 3.9%.
Raised Full-Year Guidance
Increased 2026 operational sales guidance to a range of 5.9%–6.9% (midpoint $100.2B, 6.4%) and reported sales growth estimate 6.5%–7.5% (midpoint $100.8B, 7%). Adjusted operational EPS guidance raised $0.02 to $11.30–$11.50 (midpoint +5.7%); reported adjusted EPS midpoint $11.55 (+7.1%).
Innovative Medicine Strong Growth and New Launch Momentum
Innovative Medicine sales $15.4 billion, up 7.4% operationally despite ~920 bps STELARA headwind. Ten brands delivered double-digit growth; 28 platforms or products each generate at least $1B in annual revenue. Notable new launches and approvals (ICOTYDE, TECVAYLI+DARZALEX FASPRO approval, RYBREVANT FASPRO subcutaneous approval).
High-Growth Product Performance (Oncology & Immunology)
DARZALEX sales ~$4.0B, up ~18% (17.8% reported); CARVYKTI ~ $600M, +57.4%; TECVAYLI +30.1% (sequential +14.2%); TALVEY +72.8%; RYBREVANT+LAZCLUZE $257M, +80.5% (sequential +18.8%); ERLEADA +16.2%. TREMFYA up ~63.8% and projected to exceed $10B peak sales.
Breakthrough Launch of ICOTYDE
ICOTYDE approved for first-line plaque psoriasis (oral IL‑23 peptide). Day-one launch with first patient on therapy within 24 hours; ~1,500 prescriptions and >1,000 unique prescribers in early launch period. Management calls it a potential multi‑billion dollar asset and a market-expanding systemic-first choice.
MedTech Growth and New Product Innovation
MedTech sales $8.6 billion, +4.6% operationally. Strong segments: electrophysiology +9.5% (new VARIPULSE launches), Abiomed +14.4% (Impella adoption), Shockwave +18.1% (IVL adoption). Multiple device approvals/data (VARIPULSE Pro EU launch, OMNYPULSE 12‑month positive data, TECNIS PureSee FDA approval).
INLEXZO Early Commercial Traction and Reimbursement Milestone
INLEXZO sales slightly above $30M in Q1; received permanent J‑code reimbursement April 1. Management reports ~1 in 5 eligible patients started INLEXZO in Q1; following J‑code, new patient insertions increased ~50% in week 1 and ~90% in week 2.
Cash Position, Capital Allocation and Dividend Increase
Cash & marketable securities ~$22B, debt $55B (net debt ~$33B). Q1 free cash flow ~$1.5B with full‑year free cash flow outlook ~ $21B. Board authorized a 3.1% dividend increase to $5.36/year (64th consecutive year of dividend growth).
Investments in U.S. Manufacturing & R&D
Company progressing on $55B U.S. investment plan (manufacturing, tech, R&D) with ~$12B invested through end-2025 (~22% of target) and continued significant investments in 2026.
Pipeline Visibility and Near-Term Catalysts
Multiple upcoming catalysts in 2026 across oncology, immunology and neuroscience (e.g., TREMFYA approval for psoriatic arthritis, ERLEADA data, INLEXZO expansion, JNJ‑4804 IBD data, CAPLYTA bipolar mania data) and several MedTech submissions/approvals (OTTAVA, VARIPULSE Pro U.S., Dual Energy THERMOCOOL in U.S.).
JNJ Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
JNJ Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 14, 2026 | $237.96 | $240.10 | +0.90% |
Jan 21, 2026 | $217.06 | $216.86 | -0.09% |
Oct 14, 2025 | $188.69 | $188.64 | -0.03% |
Jul 16, 2025 | $152.26 | $161.69 | +6.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Johnson & Johnson (JNJ) report earnings?
Johnson & Johnson (JNJ) is schdueled to report earning on Jul 15, 2026, Before Open (Confirmed).
What is Johnson & Johnson (JNJ) earnings time?
Johnson & Johnson (JNJ) earnings time is at Jul 15, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is JNJ EPS forecast?
JNJ EPS forecast for the fiscal quarter 2026 (Q2) is 2.86.
